Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986Maria De Santis, Joaquim Bellmunt, Graham Mead, et al.
British Journal of Cancer|March 26, 2025
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trialDesmond Yip, John Zalcberg, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trialSandro Pasquali, Sara Pizzamiglio, Nathan Touati, et al.
Annals of Surgery|April 15, 2026
Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical TrialFabio Tirotta, Lydia Champezou, Marco Fiore, et al.
JAMA Oncology|August 18, 2022
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, et al.
Chronobiology International|September 10, 2008
A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971Bruno Coudert, Christian Focan, Dominique Genet, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
The Lancet. Oncology|September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trialPenella J Woll, Peter Reichardt, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancerGordon C Jayson, Clive Mulatero, Malcolm Ranson, et al.
BMC Cancer|May 26, 2019
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupAnna Dorothea Wagner, Heike I Grabsch, Murielle Mauer, et al.
Pageof 7